262 related articles for article (PubMed ID: 16984237)
1. The long-term effects of rosiglitazone on serum lipid concentrations and body weight.
Shim WS; Do MY; Kim SK; Kim HJ; Hur KY; Kang ES; Ahn CW; Lim SK; Lee HC; Cha BS
Clin Endocrinol (Oxf); 2006 Oct; 65(4):453-9. PubMed ID: 16984237
[TBL] [Abstract][Full Text] [Related]
2. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
3. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Olansky L; Marchetti A; Lau H
Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
[TBL] [Abstract][Full Text] [Related]
4. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.
Kutoh E
Postgrad Med; 2011 Jan; 123(1):45-52. PubMed ID: 21293083
[TBL] [Abstract][Full Text] [Related]
5. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
6. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Chaudhuri A; Rosenstock J; DiGenio A; Meneghini L; Hollander P; McGill JB; Dandona P; Ilgenfritz J; Riddle M
Diabetes Metab Res Rev; 2012 Mar; 28(3):258-67. PubMed ID: 22081557
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.
Sahin M; Tutuncu NB; Ertugrul D; Tanaci N; Guvener ND
J Diabetes Complications; 2007; 21(2):118-23. PubMed ID: 17331860
[TBL] [Abstract][Full Text] [Related]
9. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
King AB; Armstrong DU
Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Scott R; Loeys T; Davies MJ; Engel SS;
Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
Patel J; Anderson RJ; Rappaport EB
Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
[TBL] [Abstract][Full Text] [Related]
14. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
Sharma SK; Verma SH
J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
[TBL] [Abstract][Full Text] [Related]
15. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.
Ko SH; Song KH; Ahn YB; Yoo SJ; Son HS; Yoon KH; Cha BY; Lee KW; Son HY; Kang SK
Metabolism; 2003 Jun; 52(6):731-4. PubMed ID: 12800099
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
Derosa G; Gaddi AV; Piccinni MN; Salvadeo S; Ciccarelli L; Fogari E; Ghelfi M; Ferrari I; Cicero AF
Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.
Berneis K; Rizzo M; Stettler C; Chappuis B; Braun M; Diem P; Christ ER
Expert Opin Pharmacother; 2008 Feb; 9(3):343-9. PubMed ID: 18220486
[TBL] [Abstract][Full Text] [Related]
18. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
[TBL] [Abstract][Full Text] [Related]
19. The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes.
Erdman DM; Cook CB; Greenlund KJ; Giles WH; El-Kebbi I; Ryan GJ; Gallina DL; Ziemer DC; Dunbar VG; Phillips LS
Diabetes Care; 2002 Jan; 25(1):9-15. PubMed ID: 11772894
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
